Lenalidomide proved effective in multisystem Langerhans cell histiocytosis

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

SZTURZ Petr ADAM Zdeněk ŘEHÁK Zdeněk KOUKALOVÁ Renata ŠLAISOVÁ Radka STEHLÍKOVÁ Olga CHOVANCOVÁ Jana KLABUSAY Martin KREJČÍ Marta POUR Luděk HÁJEK Roman MAYER Jiří

Year of publication 2012
Type Article in Periodical
Magazine / Source Acta Oncologica
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.3109/0284186X.2011.631581
Field Oncology and hematology
Keywords Langerhans cell histiocytosis; lenalidomide; PET/CT
Description Langerhans cell histiocytosis (LCH) is a rare idiopathic disease with diverse clinical manifestations ranging from a single osteolytic lesion to generalized disease. Various treatment regimens have been proposed for the multisystem type, however, with inconsistent outcomes. Herein we are the first to report on a therapy effect of a lenalidomide-based regimen in a patient with repeatedly relapsed aggressive form of multisystem LCH.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.